Laurus Labs Limited has delivered a powerful start to FY27, posting a sharp 126% year-on-year jump in consolidated net profit for the first quarter ended June 30, 2026, as its CDMO business, global expansion strategy, and operational efficiencies fuelled record growth.
The science-led pharmaceutical and biotechnology company reported a consolidated net profit attributable to equity holders of Rs. 367.60 crore, compared with Rs. 163.02 crore in Q1 FY26. Including non-controlling interests, total consolidated net profit stood at Rs. 362.07 crore.
Revenue from operations surged 29.10% year-on-year to Rs. 2,026.31 crore, compared with Rs. 1,569.57 crore in the same quarter last year. On a sequential basis, revenue increased 11.85% from Rs. 1,811.57 crore in Q4 FY26.
Profitability also strengthened significantly, with EBITDA jumping 65.55% to ₹644 crore from Rs. 389 crore in Q1 FY26. EBITDA margin expanded by 700 basis points to 31.8%, supported by a stronger product mix, higher CDMO contribution, and improved operational leverage.
Gross margins climbed to 62.7%, expanding 330 basis points year-on-year, while profit before tax more than doubled, rising 114.68% to Rs. 481.36 crore.
Laurus Labs’ Contract Development and Manufacturing Organization (CDMO) segment continued to power the company’s transformation.
Revenue from CDMO Small Molecules surged 69.37% year-on-year to Rs. 835 crore, driven by commercial API supplies, late-stage clinical project ramp-ups, and rising demand across peptides, human health, animal health, and crop science applications. The company’s active CDMO pipeline now exceeds 125 projects.
The CDMO Bio business also gained momentum, with revenue rising 20.69% to Rs. 35 crore, supported by increasing adoption of enzymatic technology solutions.
Overall, CDMO revenue reached Rs. 870 crore, marking a 66.67% year-on-year increase.
Laurus Labs’ Affordable Medicines portfolio delivered steady growth, with total revenue increasing 10.31% year-on-year to Rs. 1,156 crore.
Finished Dosage Forms (FDF) revenue rose 22.14% to Rs. 502 crore, supported by new product launches in the US market and sustained volume growth.
API revenue stood at Rs. 654 crore, growing 2.67% year-on-year.
The company’s combined Anti-Retroviral (ARV) API and FDF revenue reached Rs. 669 crore, registering 3.40% annual growth.
Laurus Labs continued to accelerate investments in future growth opportunities, with total R&D spending, including capitalised R&D expenditure, rising 74% year-on-year to Rs. 118 crore, representing 5.8% of operational revenue.
Capital expenditure during the quarter stood at 19% of sales, supporting expansion across small molecules, fermentation, peptides, gene therapy, and antibody-drug conjugate (ADC) capabilities.
The company’s large-scale fermentation facility expansion in Vizag is progressing as planned and is expected to be commissioned by Q3 FY27.
Laurus Labs also strengthened its advanced biologics pipeline by in-licensing two ADC assets from Aarvik Therapeutics for development and commercialisation in India.
The company’s joint venture with KRKA continues to progress, with Phase-I production blocks for High Potent and General OSD capabilities expected to open in mid-2027.
The company’s regulatory momentum remained strong, with cumulative Drug Master File (DMF) filings reaching 92. During Q1 FY27, Laurus Labs filed two product dossiers for developed markets, taking cumulative filings to 96.
Satyanarayana Chava, Founder & Chief Executive Officer, said: "Laurus has delivered record quarterly Revenue with expanded profitability and continued its portfolio transformation. This was driven by growing commercial deliveries within CDMO and continued strength in Affordable Medicines portfolio. During the quarter, we strengthened our Integrated offerings, niche capabilities that matter most to our clients.
'We also achieved important milestones, including agreement to in-license two Antibody Drug Conjugates (ADCs) and securing final handover of new land parcel, reinforcing our long-term growth strategy."
